IDEXX reported FY 2025 results with revenues of USD 4.3 billion (up 10.4% YoY) and income from operations of USD 1.36 billion (up 20.5% YoY), with gross profit of USD 2.66 billion. Net income was USD 1.06 billion, and cash and cash equivalents were USD 180.07 million at December 31, 2025 (down from USD 288.27 million a year earlier). Net cash provided by operating activities was USD 1.18 billion in FY 2025, while net cash used by financing activities was USD 1.16 billion, driven primarily by higher share repurchases and debt maturities, partly offset by USD 148 million of Credit Facility borrowings. By segment, Companion Animal Group $(CAG)$ revenue was USD 3.95 billion (up 10.6% YoY), led by CAG Diagnostics recurring revenue of USD 3.41 billion (up 8.9% YoY) and a jump in CAG Diagnostics capital instrument revenue to USD 200.21 million (up 51.8% YoY), which the company attributed primarily to placements of the new IDEXX inVue Dx Analyzer. IDEXX VetLab consumables revenue was USD 1.5 billion (up 14.8% YoY), while rapid assay products revenue was USD 348.95 million (down 3.0% YoY), primarily reflecting a shift of pancreatic lipase testing to the Catalyst instrument platform. Reference laboratory diagnostic and consulting services revenue was USD 1.42 billion (up 6.6% YoY). Water segment revenue was USD 201.15 million (up 8.7% YoY) and LPD revenue was USD 131.79 million (up 8.0% YoY). IDEXX said recurring diagnostic revenue represented approximately 79% of consolidated revenue in FY 2025, and highlighted growth in its premium instrument installed base as of December 31, 2025, including Catalyst at 78,000 units (from 74,000 a year earlier), Premium Hematology at 56,000 (from 52,000), SediVue Dx at 24,000 (from 21,000), and IDEXX inVue Dx at 6,000. The company also noted the IDEXX ImageVue DR50 Plus launched in North America in January 2026, and said it expects FY 2026 capital expenditures of approximately USD 180 million and a projected effective tax rate of approximately 21.3%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEXX Laboratories Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000874716-26-000038), on February 20, 2026, and is solely responsible for the information contained therein.
Comments